GlassScriptPhysician profile
Nolan Ryan Hensley
NPI 1952947558
$3,101.03
in general payments reported to CMS, 2019-2025
14 companies · $718 in 2025
The $718 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,408 · 2022: $534 · 2024: $441 · 2025: $718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,159.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $670.98 | 2021-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $505.05 | 2021-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $481.39 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $425.90 | 2021-2025 | Farxiga, Wainua |
| Amgen INC. | $264.00 | 2021-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $249.01 | 2021-2025 | Jardiance |
| Esperion Therapeutics, INC. | $208.66 | 2021-2024 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $86.16 | 2021-2025 | Camzyos, Eliquis |
| Lexicon Pharmaceuticals, INC. | $51.36 | 2024 | Inpefa |
| Scpharmaceuticals INC. | $44.20 | 2025 | |
| Pfizer INC. | $35.96 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $27.89 | 2025 | Verquvo |
| Amarin Pharma, INC. | $26.62 | 2021-2022 | |
| Irhythm Technologies, INC. | $23.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nolan Hensley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.